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Summary
Data on COPD-related healthcare resources use are rarely documented in developing
countries. This article presents data on COPD-related healthcare resource consumption in
the Middle East, North Africa and Pakistan and addresses the association of this variable
with illness severity. A large survey of COPD was conducted in eleven countries of the
region, namely Algeria, Egypt, Jordan, Lebanon, Morocco, Pakistan, Saudi-Arabia, Syria,
Tunisia, Turkey and United Arab Emirates, using a standardised methodology. A total of
62,086 subjects were screened. This identiﬁed 2,187 subjects fulﬁlling the “epidemiological”
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deﬁnition of COPD. A detailed questionnaire was administered to document data on COPD-
related healthcare consumption. Symptom severity was assessed using the COPD Assessment
Test (CAT). 1,392 subjects were analysable. Physician consultations were the most frequently
used healthcare resource, ranging from 43,118 [95%CI: 755 85,548] consultations in UAE to
4,276,800 [95%CI: 2,320,164 6,230,763] in Pakistan, followed by emergency room visits,
ranging from 15,917 [95%CI: 0 34,807] visits in UAE to 683,697 [95%CI: 496,993 869,737] in
Turkey and hospitalisations, ranging from 15,563 [95%CI: 7,911 23,215] in UAE to 476,674
[95%CI: 301,258 652,090] in Turkey. The use of each resource increased proportionally with
the GOLD 2011 severity groups and was signiﬁcantly (p < 0.0001) higher in subjects with
more symptoms compared to those with lower symptoms and in subjects with exacerbations
to those without exacerbations. The occurrence of exacerbations and the CAT score were
independently associated with use of each healthcare resource. In conclusion, the BREATHE
study revealed that physician consultation is the most frequently COPD-related healthcare
resource used in the region. It showed that the deterioration of COPD symptoms and the
frequency of exacerbations raised healthcare resource consumption.
© 2012 Elsevier Ltd. All rights reserved.
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a chronic
illness requiring long-term management. It has a major
impact on healthcare expenditure and can impose a
substantial economic burden on patients and healthcare
service providers.1 In addition, COPD has a major negative
impact on the daily lives of patients, as it impairs individual
well-being, functional status and work production.1
It is important to collect standardised information on the
healthcare resources used and to identify which factors are
most involved in driving consumption with respect to the
local speciﬁcities of each country or region of the world.
From this perspective, many studies performed in developed
countries have shown that physician consultations and
hospitalisations constitute the principal outlay in terms
of healthcare resources in the management of COPD.2 4
In addition, disease exacerbations in COPD make a
major contribution to resource consumption and related
cost.5 In the USA, the National Heart, Lung, and Blood
Institute (NHLBI) estimated the total costs attributable to
COPD to over $38 billion in 2005, with a direct cost of
$22 billion.6 The direct costs per patient ranged from $2,700
to $5,900 annually.6 It has also been reported that the use
of healthcare resources by patients with COPD in the USA
is higher than that of patients with other chronic diseases
presenting similar demographic and morbidity features.2
The SCOPE study, performed in France in 2001, revealed
that the total medical cost of COPD was €3.5 billion with
a direct cost per patient of €1,800.7 In this study, the
main cost drivers identiﬁed were hospitalisations (35%)
and medications (31%) whereas physician visits contributed
only 4% of the total direct cost.7
Information on the use of COPD-related healthcare
resources in developing countries is limited, despite the
important impact that COPD may have on patients, on
healthcare systems and on the economies of these countries.
To our knowledge, no studies describing COPD-related
healthcare resources have been published in the Middle East
and North Africa (MENA) region.
We have recently performed a large epidemiological
survey of patients presenting COPD-related symptoms in the
general populations of eleven countries in the MENA region
using a standardised methodology, the BREATHE study.8 This
survey interviewed over 60,000 individuals aged 40 years
and identiﬁed 2,187 subjects fulﬁlling an epidemiological
deﬁnition of COPD. These subjects were invited to
answer a detailed questionnaire collecting information on
risk factors, disease history, clinical symptoms, impact on
daily life, disease management and healthcare resource
consumption. This article presents the data on resource
utilisation and addresses the association of this variable
with the severity of the illness. Since costing conventions
for healthcare expenditure and the structure of healthcare
provision differ widely between participating countries, no
attempt has been made in the present analysis to quantify
resource use in monetary terms, although this may be
addressed in future publications at the individual country
level.
Methods
This was a cross-sectional observational survey of COPD
conducted in a random sample of the general population
of eleven countries: (Algeria, Egypt, Jordan, Lebanon,
Morocco, Pakistan, Saudi Arabia, Syria, Tunisia, Turkey
and UAE) between June 2010 and December 2011. The
methodology used in the study is presented in detail in
another article in this supplement.8 The present article
presents the data collected on COPD-related healthcare
consumption.
Study sample
A general population sample of 10,000 subjects in each
country or zone was generated from random telephone
numbers. A structured interview was proposed to all eligible
subjects by telephone. Subjects not domiciled in the country
or zone or those of foreign origin resident in the country for
less than six months at the time of the study were excluded,
as were those who had comorbid mental illness.
All subjects (males or females) aged  40 years, who
agreed to participate in the study and who reported
respiratory symptoms fulﬁlling the epidemiological deﬁni-
tion of COPD were eligible for the analysis. As described
previously in this supplement,8 this deﬁnition required two
criteria to be fulﬁlled. The ﬁrst criterion was EITHER a
COPD and associated healthcare resource consumption in the MENA region S77
diagnosis of COPD, emphysema or chronic bronchitis OR the
presence of coughing with phlegm or sputum (productive
cough), breathlessness or symptoms consistent with chronic
bronchitis. The second criterion was a lifetime smoking
exposure of 10 pack·years.
Data collection
When initial telephone contact had been made, the
interviewer explained to the interviewee the goal of the
study and the next steps. Subjects who agreed to participate
in the study completed a ﬁrst screening questionnaire which
collected data on demographics, respiratory symptoms and
smoking habits.8 10
Subjects fulﬁlling the epidemiological deﬁnition of COPD
were considered to have COPD and were invited to
undergo a second, more detailed telephone questionnaire
on the disease (detailed COPD subject questionnaire). This
second questionnaire consisted of 77 questions collecting
information on risk factors, comorbidities, disease history,
clinical symptoms, impact on daily life and disease man-
agement. They were also invited to complete an additional
COPD-related healthcare consumption questionnaire which
documented data on healthcare consumption of COPD
subjects together with the associated cost. However, only
data from the detailed COPD questionnaire are presented in
this article, since the number of responders to the speciﬁc
cost questionnaire was low compared to the response rate
for the detailed COPD questionnaire and since no monetary
valuation was required for the present analysis at the
regional level.
In the detailed COPD questionnaire, information was
collected on diagnosis (whether diagnosed with COPD and
if so at what age), consultations (how often, type of
physician seen, other health professionals), hospitalisations
(how many times and how many nights), emergency room
visits (how many visits), lung function testing (spirometry
and peak ﬂow meter whether tested and how often),
paraclinical tests, use of oxygen therapy (yes/no and
frequency) and medication use (checklist of speciﬁc
respiratory medicines, use of over-the-counter medications,
antibiotic use for respiratory infections).
Determination of resource consumption by country
Total healthcare resource consumption attributable to
COPD was determined by extrapolation of the rates of
use documented in the BREATHE study to the total
population of each country aged forty years or more.
The demographic data for the total population were
obtained from the most recent national censuses in each
country.11 22 Data on the age-adjusted prevalence of COPD
according to the epidemiological deﬁnition used in the
BREATHE study correspond to those reported elsewhere
in this supplement.10 Data on the absolute number and
the proportion of COPD patients who were hospitalised or
admitted to an emergency room due to their respiratory
condition have been reported in the article dedicated
to disease management elsewhere in this supplement.23
These source data used to extrapolate national healthcare
resource consumption are summarised in Table 1.
Determination of exacerbations, symptom severity
and GOLD category
An exacerbation was taken to have occurred in the previous
six months if the subject fulﬁlled any of the three following
criteria:
• Criterion 1: In the last 6 months, have you been told
by your physician that you have had worsening of your
“Respiratory Condition”? YES
• Criterion 2: In the last 6 months, have you been told by
your physician that you have had acute bronchitis? YES
• Criterion 3: In the last 6 months, what aspects of your
“Respiratory Condition” have worsened? (cough during the
daytime, cough during the night, phlegm, breathlessness
or shortness of breath and fatigue, ability to perform
regular activities) At least two symptoms cited
Symptom severity was assessed using the COPD Assess-
ment Test (CAT),24,25 which consists of eight items assessing
health status impairment in COPD. The ﬁnal score for
this test ranges from 0 to 40. All subjects fulﬁlling the
epidemiological deﬁnition of COPD were also asked to
complete the CAT.
Subjects were then classiﬁed into one of four groups
depending on their CAT score and risk of exacerbations,
according to the recommendations of the 2011 GOLD re-
port26 (Fig. 1). However, since the number of exacerbations
was not documented, the GOLD classiﬁcation was adapted
according to the presence or absence of exacerbations over
the previous six months.
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Figure 1. Classiﬁcation of COPD subjects in this study according
to their CAT score and exacerbation history (adapted from the
2011 GOLD report26). Group A: low risk, less symptoms: no
exacerbations and CAT score <10; Group B: low risk, more
symptoms: no exacerbations and CAT score 10; Group C:
high risk, less symptoms: 1 exacerbation and CAT score <10;
Group D: high risk, more symptoms: 1 exacerbation, and
CAT score 10.
Statistical analysis
For national resource consumption, the total number
of units of consumption was calculated together with
their 95% conﬁdence intervals (95%CI). Total healthcare
consumption was compared between CAT score categories
(<10 and 10) and exacerbation category (presence or
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absence in the previous six months) using the c2 test, and
per capita consumption compared between GOLD severity
groups using one-way analysis of variance (ANOVA). To
assess the impact of exacerbations and symptom severity,
these variables were categorised as presence or absence of
exacerbations in the previous six months and CAT score of
<10, 10 19, 20 29 or 30. These variables were entered
into a multivariate logistic regression analysis which was
adjusted for gender and age by class (40 50 years, 50 60
years and 60 years). Odds ratios together with their 95%CI
were derived.
Results
Study sample
A total of 1,392 subjects were interviewed, corresponding
to 63.6% of the COPD population (n = 2,187). No relevant
differences in terms of age, gender and COPD symptoms
(productive cough, breathlessness or symptoms consistent
with chronic bronchitis) were found when comparing the
COPD population who completed the detailed questionnaire
with all 2,187 subjects who fulﬁlled the epidemiological
deﬁnition of COPD. The demographic features of these
interviewees are presented by country in Table 2. Consistent
with the demographics of the COPD population, the
number of men was higher than the number of women
(sex ratio 3.1) and the number of subjects aged 60 years
was lower than the two other age groups. Half of the study
population reported that they considered themselves to be
in good, very good or excellent health (696/1388; 50.1%),
although around one half reported at least one comorbidity
(688/1392; 49.4%). Furthermore, around two thirds of
subjects were overweight (643/996; 64.5%).
Global healthcare resource consumption
The extent of use of healthcare resources reported
by subjects in the COPD population in the BREATHE
study extrapolated to the total number of people aged
40 years in each participating country is presented in
Table 3. Overall, physician consultations were the most
frequently used healthcare resource consumption item in
the MENA region, followed by emergency room visits and
hospitalisations. The number of physician consultations for
respiratory conditions used in the BREATHE study varied
from 43,118 [95%CI: 755 85,548] in UAE to 4,276,800
[95%CI: 2,320,164 6,230,763] in Pakistan. The number
of emergency room visits ranged from 15,917 [95%CI:
0 34,807] visits in UAE to 683,697 [95%CI: 496,993 869,737]
in Turkey. The same tendency was observed for hospitalisa-
tions, which varied from 15,563 [95%CI: 7,911 23,215] in
UAE to 476,674 [95%CI: 301,258 652,090] in Turkey.
Symptoms, exacerbations and resource
consumption
Healthcare resource consumption was evaluated according
to CAT score and to the presence or absence of ex-
acerbations in the previous year (Table 4). Overall, the
use of healthcare resources was signiﬁcantly higher when
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comparing subjects with more symptoms (score CAT 10)
to those with lower symptoms (p < 0.0001) and when
comparing subjects with exacerbations to those without
exacerbations (p < 0.0001).
Subjects were classiﬁed into four severity groups based
on their CAT score and on the presence of exacerbations,
following the GOLD 2011 severity classiﬁcation, (Fig. 2).
Healthcare expenditure increased proportionally with the
GOLD severity group, with subjects with a CAT score 10
and experiencing exacerbations (Group D) having the
highest expenditure. This was particularly striking for
hospitalisations and emergency visits, which were six times
more frequent in this group than in subjects with a
CAT score <10 and who did not experience exacerbations
(Group A). For all three types of expenditure, the association
between GOLD group and resource consumption was highly
statistically signiﬁcant (p < 0.001; ANOVA).
Factors associated with healthcare resources
CAT score and exacerbations, together with age and gender,
were entered into a multivariate logistic regression analysis
of resource consumption; the results are presented in Fig. 3.
The occurrence of exacerbations was signiﬁcantly associ-
ated with physician consultations, emergency room visits
and hospitalisations, with odds ratios ranging from 1.77
to 2.97 with respect to the reference group with no exacer-
bations. With respect to the CAT score, an overall trend was
observed for increased likelihood of healthcare consumption
for all three healthcare variables. This association reached
statistical signiﬁcance for hospitalisations and emergency
room visits when the CAT score was higher than 20. No
independent associations with resource utilisation were
observed for age or gender, with the exception of male
gender which appeared to be independently associated with
a lower risk of hospitalisation (OR: 0.62 [95%CI: 0.46 0.93].
Moreover, a trend for increased hospitalisation with age was
also observed, but this was not statistically signiﬁcant.
The presence of comorbidities was also a factor associated
with increased use of healthcare resources. Subjects with
comorbidities were more likely to be hospitalised or make
an emergency visit than subjects without comorbidities,
and marginally more likely to consult a physician (Table 5).
This was the case both for subjects with cardiovascular
comorbidities and for those with diabetes.
Discussion
This study assessed the healthcare resources related to
COPD used in eleven countries in the MENA region in the last
year. The study evaluated subjects fulﬁlling the epidemio-
logical deﬁnition of COPD. Healthcare resources consumed
in each participating country, as well as the potential factors
that inﬂuence this consumption, have been described.
The results of the BREATHE study revealed that physician
consultations were the principal healthcare resources used
in the MENA region, followed by emergency room visits
and hospitalisations. The healthcare consumption increased
with GOLD severity grade, particularly for hospitalisations
and emergency visits. Although costs were not evaluated
in this analysis, it may be anticipated that hospitalisations,
which were relatively frequent and have a high unit cost,
may contribute the largest segment of cost.
The BREATHE study found that a total of 9,386,540
physician consultations, 1,696,433 emergency room visits
and 1,613,079 hospitalisations are attributable to COPD
in the participating countries of the MENA region. This
hierarchy of resource use has also been reported in
several other studies. For example, a study performed
in the USA in 2000 reported that COPD was the cause
of eight million physician consultations, over two million
emergency room visits and near one million hospitalisations
per year.27The same hierarchy was also found in an analysis
of the burden of COPD in the Netherlands using data
from the Confronting COPD international survey.28 Overall,
the analysis of healthcare resources found in that survey,
which was conducted in seven countries in North America
and Europe in 2000, revealed that physician consultations
were also the most frequently used resource followed by
hospitalisations and emergency room visits.29 Nonetheless,
in studies where resource utilisation has been valued,
hospital inpatient care, which has the highest unit cost, is
responsible for the highest expenditure outlay related to
COPD.29 31
In developing countries, data on healthcare resource
use attributable to COPD are sparse, making any direct
comparison with the ﬁndings of the BREATHE study very
difﬁcult. The majority of available data on COPD-related
healthcare resource consumption in these countries relate
to frequency of use. For example, in an international study
including Turkey and analysing the burden of COPD,30 the
reported rates of healthcare resource use in subjects with
a physician-assigned diagnosis of COPD in Turkey were
~61% for specialist consultations, ~47% for primary care
physician consultations, ~22% for emergency visits and
~15% for hospitalisation. These rates are in the same order
of magnitude as those reported in the BREATHE study.
Even taking into account the different population sizes
of participating countries, the BREATHE study showed
that healthcare resource consumption differed between
countries of the MENA region. This difference might be
explained by local speciﬁcities regarding the healthcare
system and the heterogeneous distribution of healthcare
resources within countries. For example, the healthcare
insurance system is different between countries (principally
public sector in Algeria and Pakistan, principally private in
UAE and Lebanon). One aspect of this is physical access to
care facilities, which may differ between small urbanised
countries with a high population density, such as Lebanon,
and countries with large rural areas where hospitals may
be far away and difﬁcult to reach. This is a particular
issue for diseases such as COPD in which mobility is
affected. Another issue is the extent of reimbursement
for physician consultation and treatments, which varies
markedly between participating countries. Such differences
may inﬂuence the decision to consult a physician or agree
to hospitalisation particularly if the unit cost is considered
expensive or if the reimbursement rate is low. A recent
analysis of COPD-associated healthcare resource in the
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Table 4
Distribution of use of healthcare resources according to CAT scores and exacerbations
CAT score
<10 10 Total p -value
Exacerbations
No Yes Total p -value
Physician consultation 233 781 1,014 731 661 1392
At least one in
previous year
128 (54.9%) 542 (63.6%) 670 (66.1%) <0.0001 343 (46.9%) 509(77.0%) 852 (61.2%) <0.0001
[95%CI] [48.5 61.3%] [60.2 66.9%] [63.2 69.0%] [43.3 50.5%] [73.8 80.2%] [58.6 63.8%]
Type of physician
consulted
132 554 686 351 516 867
General practitioner 36 (27.3%) 119 (21.5%) 155 (22.6%) NS 71 (20.2%) 113 (21.9%) 184 (21.2%) NS
[95%CI] [19.7 34.9%] [18.1 24.9%] [19.5 25.7%] [16.0 324.4%] [18.3 25.5%] [18.5 23.9%]
Pulmonologist 49 (37.1%) 258 (46.6%) 307 (44.8%) 162 (46.2%) 235 (45.5%) 397 (45.8%)
[95%CI] [28.9 45.4%] [42.4 50.7%] [41.0 48.5%] [41.0 51.4%] [41.2 49.8%] [42.5 49.1%]
Other speciality 47 (35.6%) 177 (31.9%) 224 (32.7%) 118 (333.6%) 168 (32.6%) 286 (33.0%)
[95%CI] [27.4 43.8%] [28.1 35.8%] [29.1 36.2%] [28.7 38.5%] [28.6 36.6%] [29.9 36.1%]
Mean number of
consultations
3.11±2.77 3.22±3.47 3.20±3.37 NS 2.74±3.22 3.53±3.63 3.39±3.57 NS
Hospitalisations 233 781 1,041 731 661 1392
At least one in
previous year
26 (11.2%) 178 (22.8%) 204 (20.1%) 0.0001 111 (15.2%) 173 (26.2%) 284 (20.4%) <0.0001
[95%CI] [7.1 15.2%] [19.8 25.7%] [17.7 22.6%] [12.6 17.8%] [22.8 29.6%] [18.3 22.5%]
Mean number of
hospitalisations
0.74±0.96 2.72±4.36 2.46±4.13 0.0319 1.74±1.99 2.64±4.30 2.32±3.66 NS
Emergency room visits 233 781 1,014 731 661 1392
At least one in
previous year
15 (6.4%) 156 (20.0%) 171 (16.9%) <0.0001 103 (14.1%) 146 (22.1%) 249 (17.9%) <0.0001
[95%CI] [3.3 9.6%] [17.2 22.8%] [14.6 19.2%] [11.6 16.6%] [18.9 25.3%] [15.9 19.9%]
Mean number of
visits
1.87±1.46 3.96±6.02 3.78±5.79 NS 3.32±6.10 3.64±4.20 3.51±5.07 NS
Ye
s
N
o
E
xa
ce
rb
a

o
n
s
<10 ≥10
CAT score
Cons/year Cons/year
Cons/year Cons/year
Hosp/year Hosp/year
Hosp/year Hosp/year
EV/year EV/year
EV/year EV/year
202 257
152 123
12 78
6 24
8 94
15 45
100 100
100 100
200 200
200 200300 300
300 3000 0
0 0
Figure 2. Healthcare distribution according to GOLD severity group. Data are presented as per capita consumption ×100. Cons/year,
number of physician consultations per year; Hosp/year, number of hospitalisations per year; EV/year, number of
emergency room visits per year.
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Figure 3. Variables associated with healthcare resources used identiﬁed by multiple logistic regression analysis. Data are presented
as Forest diagrams showing odds ratios with their 95% conﬁdence intervals.
Table 5
Distribution of use of healthcare resources according to comorbidities
No comorbidities Any comorbidity p Diabetes Cardiovascular
comorbidity
N = 704 N= 688 N= 250 N= 344
Physician consultation 413 (58.7%) 439 (63.8%) 0.049 160 (64.0%) 218 (63.4%)
Number of consultations 3.67±4.03 3.15±3.12 0.218 2.98±2.80 3.05±3.00
Hospitalisation 100 (14.2%) 184 (26.7%) <0.0001 66 (26.4%) 87 (25.3%)
Number of hospitalisations 2.03±2.57 2.45±4.07 0.401 2.54±5.57 2.01±3.90
Mean number of nights hospitalised 5.07±7.75 6.15±9.05 0.370 7.33±11.83 7.08±11.21
Emergency room visits 107 (15.2%) 142 (20.6%) <0.008 56 (22.4%) 66 (19.2%)
Number of visits 3.05±6.20 3.85±4.02 0.219 3.60±4.00 3.92±4.42
USA revealed that COPD subjects were more likely to
consider that the cost related to COPD was an obstacle
to medical care than subjects without COPD (34.0% versus
17.0% respectively).32 In addition, these disparities might be
inﬂuenced by the number of physicians in each country and
by the healthcare sector (specialist or generalist, hospital
or community) in which COPD is generally managed. The
difference in healthcare resource consumption between
countries in the BREATHE study might also be explained
by differences in disease severity or in the nature of
the presenting symptoms, as described elsewhere in this
supplement.10 In this respect, a recent study performed
in Turkey in 497 stable COPD patients suggested that
reducing breathlessness was more of an incentive to seeking
treatment than was controlling productive cough.33
It has been reported in the literature that COPD drives
more healthcare consumption than many other chronic
diseases. For example, in the United Kingdom, it was
reported that the number of physician consultations for
respiratory diseases is over three times as high as that for
diseases of the circulatory or digestive system. In addition,
COPD accounted for around ﬁve times as many hospital
admissions as asthma, which has a higher prevalence than
COPD in the UK.4
Not surprisingly, the BREATHE study showed that, in
the MENA region, exacerbations of COPD were the major
driver of physician consultations, emergency room visits
and hospitalisations. This result was consistent with many
other studies performed in North America and Europe.34,35
In addition, the BREATHE study indicated that symptom
severity as measured by the CAT also contributed to
resource consumption, again consistent with previous
studies.7,30 This illustrates the importance of management
strategies for COPD that address both reduction of the
risk of exacerbations and the reduction of symptom
severity. Effective treatments for achieving both these goals
exist, as recommended in the most recent (2011) GOLD
recommendations.26 However, as observed in the BREATHE
study,23 most individuals reporting COPD symptoms in the
MENA region are not receiving this standard of care. It is
an important message for health system decision-makers
that investments to ensure optimal management of COPD
may generate important long-term cost savings to the health
system through reduction in the need for hospitalisation and
emergency room visits. The data collected in the BREATHE
study may be of use for healthcare policy makers in setting
priorities with respect to cost minimisation programmes,
prevention programmes and access to care.
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Another factor found to be associated with healthcare
resource utilisation was the presence of comorbidities. This
ﬁnding is consistent with a number of other studies.36 38
The impact that such comorbidities may have on morbidity
and mortality associated with COPD is being increasingly
recognised as part of the overall burden of disease and an
important driver of cost of the disease.38 We also found that
male gender appeared to be independently associated with
a lower risk of hospitalisation. This may be related to loss
of income due to the absence of social security and the man
usually being the only breadwinner in the household.
Given the growing proportion of individuals in participat-
ing countries who smoke and the increase in life expectancy,
the use of healthcare resources and its associated costs
are likely to increase in the next decades. In this
context, effective public health strategies together with
cost minimisation programmes are needed to ensure timely
diagnosis of COPD and adequate treatment over the long
term in order to reduce the number of hospitalisations and
emergency visits due to disease exacerbations, which are
the principal drivers of cost in the management of COPD.
This study presents certain limitations. One of these
relates to the source of the data which was from patient
self-report. This may introduce a source of anamnestic error
and also some inaccuracy due to the lack of physician
ascertainment. Data on direct or indirect costs related to
each healthcare resource used were not exploited in this
analysis, since costing conventions are extremely diverse
between countries in the region and not always standardised
within individual countries. For this reason, we have no
overall information on the global economic cost of COPD
in the MENA region. Nonetheless, for certain individual
countries, it should be possible to attribute costs and thus
deﬁne the potential impact of COPD on the economy of
each country. Such national analyses will be performed and
published at a later stage. A further consequence of the
method of data collection is the deﬁnition of exacerbations
used in the study. We have tried to construct an
operational deﬁnition of exacerbations based on subject’s
experience, with no information available directly from the
physician, and using a language appropriate for the general
population. The proportion of patients with exacerbations
identiﬁed using this deﬁnition is within the range of that
reported in other studies in which exacerbations were
ascertained by the physician.34,39 In addition, subjects with
exacerbations used more healthcare resources than those
without, supporting the face validity of the deﬁnition.
Nonetheless, we cannot rule out some over-estimation of
COPD exacerbations due to subjects potentially reporting
worsening of respiratory symptoms caused by comorbidities.
Our deﬁnition has not been previously validated, and it
would be useful to compare the performance of this
deﬁnition against physician-ascertained exacerbations in a
future study.
In conclusion, the BREATHE study identiﬁed two factors
which drive healthcare resource consumption in the
MENA region, namely the severity of COPD symptoms
(assessed with the CAT questionnaire) and the frequency
of exacerbations. Given the importance of these factors,
and as recommended by the recent GOLD guidelines, it
seemed to be important to assess each of them as a part
of an individualised approach in order to optimise the
management of COPD and thus reduce the level of use of
healthcare resources in the MENA region.
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